Abstract: The present invention relates to a flow assay method in a liquid medium for an object (or element) of interest via the formation of aggregates of particles that are surface-functionalized by at least one functionalizing molecule, or receptor, specific for said object of interest.

Abstract: The present invention concerns a device for analyzing biological parameters from a sample (6) comprising (i) first transferring means (5, 20, 25), (ii) first preparing means (7), (iii) means for measuring cellular components (8), (iv) second preparing means (10, 11, 22, 23, 24) capable of carrying out, on a sample from the first preparing means (7), at least one dilution with an assay reagent (R3) comprising particles functionalized at the surface with at least one ligand specific to at least one analyte of interest, (v) immunodetection measurement means (30, 31) capable of assaying at least one analyte of interest by measuring the aggregation of functionalized particles, said device further comprising (i) second transferring means (4, 21, 22, 26) at least partially separate from the first transferring means (5, 20, 25) and (ii) means for applying a magnetic field (28) capable of causing, by magnetic interaction, an acceleration of the aggregation of said functionalized particles, which comprise magnetic coll

Abstract: The present invention relates to a method for compensating for the breakdown of a reagent stored in an aqueous phase comprising at least one fluorescent compound and enabling the identification of particles, including the steps of: (i) measuring the fluorescence level FLUOm(t) of particles marked with said reagent; (ii) measuring the absorbance at at least one wavelength of a solution of said reagent, at a time t close to the time of said fluorescence level FLUOm(t) measurements, so as to determine at least one current optical density DO(t) of the reagent; and (iii) calculating a correction of the fluorescent level measurements using said at least one current optical density DO(t) and at least one initial optical density DO(0) of the reagent that has not been broken down. The invention also relates to a biological analysis device implementing the method.

Abstract: The present invention relates to a flow assay method in a liquid medium for an object (or element) of interest via the formation of aggregates of particles that are surface-functionalized by at least one functionalizing molecule, or receptor, specific for said object of interest.

Abstract: The present invention relates to a method for compensating for the breakdown of a reagent stored in an aqueous phase comprising at least one fluorescent compound and enabling the identification of particles, including the steps of: (i) measuring the fluorescence level FLUOm(t) of particles marked with said reagent; (ii) measuring the absorbance at at least one wavelength of a solution of said reagent, at a time t close to the time of said fluorescence level FLUOm(t) measurements, so as to determine at least one current optical density DO(t) of the reagent; and (iii) calculating a correction of the fluorescent level measurements using said at least one current optical density DO(t) and at least one initial optical density DO(0) of the reagent that has not been broken down. The invention also relates to a biological analysis device implementing the method.

Abstract: The present invention concerns a device for analyzing biological parameters from a sample (6) comprising (i) first transferring means (5, 20, 25), (ii) first preparing means (7), (iii) means for measuring cellular components (8), (iv) second preparing means (10, 11, 22, 23, 24) capable of carrying out, on a sample from the first preparing means (7), at least one dilution with an assay reagent (R3) comprising particles functionalized at the surface with at least one ligand specific to at least one analyte of interest, (v) immunodetection measurement means (30, 31) capable of assaying at least one analyte of interest by measuring the aggregation of functionalized particles, said device further comprising (i) second transferring means (4, 21, 22, 26) at least partially separate from the first transferring means (5, 20, 25) and (ii) means for applying a magnetic field (28) capable of causing, by magnetic interaction, an acceleration of the aggregation of said functionalized particles, which comprise magnetic coll

Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.

Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.

Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.

Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.

Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.

Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.

Abstract: The invention concerns a novel method for producing hydroxylated and/or acetylated steroid comprising steps which consist in: culturing yeasts on a medium comprising at least a precursor of such hydroxylated and/or acetylated steroids; then isolating the hydroxylated and/or acetylated steroids from the medium after bioconversion. Said method is characterized in that said yeasts are yeasts transformed so as to express the product of Cyp7b gene. The invention also concerns the modified yeast strains.

Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.

Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20&agr;HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.

Abstract: A subject of the invention is a modified yeast strain in which the acetyl-CoA pregnenolone acetyltransferase (APAT) activity is eliminated by altering the gene coding for this activity with resultant stabilization of 3&bgr;-hydroxysteroids.

Abstract: A subject of the invention is a modified yeast strain in which the acetyl-CoA pregnenolone acetyltransferase (APAT) activity is eliminated by altering the gene coding for this activity with resultant stabilization of 3&bgr;-hydroxysteroids.

Abstract: A subject of the invention is a modified yeast strain in which the acetyl-CoA pregnenolone acetyltransferase (APAT) activity is eliminated by altering the gene coding for this activity with resultant stabilization of 3&bgr;-hydroxysteroids.

Abstract: The present invention relates to the production, by recombinant DNA techniques, of derivatives of basic fibroblast growth factor (bFGF). These derivatives of bFGF can act as antagonists and/or superagonists of the wild type molecule in the angiogenic process. These derivatives, as well as wild type bFGF, may be prepared by the use of strains or E. coli which have been transformed with plasmids carrying nucleotide sequence coding for human and bovine bFGF and their derivatives.